Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.
Pharmaceutical firm Sanofi has made an €80m ($91.5m) equity investment in Germany-based immuno-oncology therapy developer Biontech in connection with the extension of a research and development collaboration agreement. Spun out of Johannes Gutenberg University Mainz in 2008, Biontech is developing immunotherapies to treat cancer and infectious diseases. It formed a research partnership with Sanofi in…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
